Markets:

Overview

News

Currencies

International

Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

0.8770 -0.0131 (-1.47%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

InMed Pharmaceuticals Committed To Growing Market Reach, Product Portfolio ↗

March 28, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

63 Biggest Movers From Yesterday ↗

March 25, 2022

Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet...

Via Benzinga

InMed Pharmaceuticals Makes Changes In Management ↗

March 18, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

InMed Pharmaceuticals' Issues Annual Shareholder Letter ↗

January 05, 2022

InMed Pharmaceuticals (NASDAQ:

Via Benzinga

InMed Launching Additional Rare Cannabinoids In Response To Demand ↗

March 17, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....

Via Benzinga

InMed Pharmaceuticals Expanding Portfolio In Rare Cannabinoid Market ↗

March 04, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 02, 2022

Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...

Via Benzinga

InMed's Evolution To Commercial Sales Featured In Research Report ↗

February 17, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....

Via Benzinga

InMed Names BayMedica VP Of Sales, Releases Q2 2022 Report ↗

February 16, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a...

Via Benzinga

InMed Positioned To Offer Rare Cannabinoid Manufacturing Technologies ↗

February 15, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....

Via Benzinga

InMed Pharmaceuticals To Release Q2 Financial Report, Update ↗

February 11, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a...

Via Benzinga

InMed Pharmaceuticals Strengthens Leading Role In Rare Cannabinoid Market ↗

February 04, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cannabicitran is the first of four new rare cannabinoids InMed...

Via Benzinga

InMed Pharmaceuticals Defining Value Of Rare Cannabinoids In Pharma Space ↗

February 03, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

InMed Pharmaceuticals Expands Rare Cannabinoid Product Portfolio to Launch CBT ↗

January 20, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a...

Via Benzinga

4 Penny Stocks Insiders Are Buying ↗

January 07, 2022

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste...

Via Benzinga

InMed Pharmaceuticals to Present at Tribe Public's Webinar Event ↗

December 30, 2021

InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and...

Via Benzinga

InMed Pharmaceuticals Announces Publication of Article on CBN as Possible Glaucoma Treatment ↗

December 20, 2021

InMed Pharmaceuticals (NASDAQ:

Via Benzinga

InMed Pharmaceuticals' Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment ↗

December 10, 2021

InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following...

Via Benzinga

InMed Pharmaceuticals Targeting Potential Therapeutics Addressing Unmet Needs ↗

December 01, 2021

InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio...

Via Benzinga

Topics Intellectual Property

InMed Pharmaceuticals Releases Q1 2022 Financial Results, Business Update ↗

November 29, 2021

InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 ↗

November 29, 2021

Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE:

Via Benzinga

InMed Pharmaceuticals Announces Participation in Upcoming Cannabis Conference ↗

November 23, 2021

InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, will be participating in the 4th annual Cowen Cannabis...

Via Benzinga

Topics Cannabis

54 Biggest Movers From Yesterday ↗

November 19, 2021

Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company...

Via Benzinga

Welcome to the Party $INM! Competition or Compliment to $SNDL? — Cannabis Daily November 18, 2021 ↗

November 18, 2021

The Best Daily Overview Of The Cannabis Space South Dakota lawmakers recommend bill to legalize marijuana. New York ban...

Via Benzinga

Topics Cannabis

44 Stocks Moving In Thursday's Mid-Day Session ↗

November 18, 2021

Gainers Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

November 18, 2021

Good morning, investor! We're getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday!

Via InvestorPlace

24 Stocks Moving in Thursday's Pre-Market Session ↗

November 18, 2021

Gainers Sono Group N.V. (NASDAQ: SEV) rose 33% to $50.80 in pre-market trading. Sono Group shares climbed 155% on Wednesday after the company priced its IPO at $15 per share....

Via Benzinga

Topics Initial Public Offering

InMed Pharmaceuticals Working to Address Rare Cannabinoid Opportunities ↗

November 17, 2021

InMed Pharmaceuticals (NASDAQ:

Via Benzinga

InMed Pharmaceuticals Files Patent Application for Treatment of Neurodegenerative Diseases with Rare Cannabinoid ↗

November 11, 2021

InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabi...

Via Benzinga

Topics Intellectual Property

InMed Pharmaceuticals Inc. Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid ↗

November 03, 2021

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development, and commercialization of rare cannabinoids, today announced its filing of an international patent...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

Headline News about InMed Pharmaceuticals Inc. - Common Shares

Starting at $3.75/week.

Subscribe Today